After finishing at $4.54 in the prior trading day, Allogene Therapeutics Inc (NASDAQ: ALLO) closed at $4.63, up 1.98%. In other words, the price has increased by $+0.0900 from its previous closing price. On the day, 2636558 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our goal is to gain a better understanding of ALLO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.58 and its Current Ratio is at 12.58. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.15.
On December 08, 2023, Citigroup started tracking the stock assigning a Buy rating and target price of $7.Citigroup initiated its Buy rating on December 08, 2023, with a $7 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 18 when MESSEMER DEBORAH M. sold 18,640 shares for $2.70 per share. The transaction valued at 50,317 led to the insider holds 62,456 shares of the business.
Mayo Stephen sold 10,000 shares of ALLO for $42,855 on Aug 07. The Director now owns 25,328 shares after completing the transaction at $4.29 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALLO now has a Market Capitalization of 779.12M and an Enterprise Value of 388.57M. For the stock, the TTM Price-to-Sale (P/S) ratio is 4100.72 while its Price-to-Book (P/B) ratio in mrq is 1.34. Its current Enterprise Value per Revenue stands at 2.17k whereas that against EBITDA is -1.24.
Stock Price History:
Over the past 52 weeks, ALLO has reached a high of $7.14, while it has fallen to a 52-week low of $2.23. The 50-Day Moving Average of the stock is 3.5394, while the 200-Day Moving Average is calculated to be 3.9889.
Shares Statistics:
The stock has traded on average 3.09M shares per day over the past 3-months and 2.13M shares per day over the last 10 days, according to various share statistics. A total of 144.44M shares are outstanding, with a floating share count of 103.86M. Insiders hold about 38.28% of the company’s shares, while institutions hold 61.11% stake in the company. Shares short for ALLO as of Jan 31, 2024 were 23.09M with a Short Ratio of 7.47, compared to 31.32M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 13.72% and a Short% of Float of 20.20%.
Earnings Estimates
Its stock is currently analyzed by 16 different market analysts. On average, analysts expect EPS of -$0.45 for the current quarter, with a high estimate of -$0.34 and a low estimate of -$0.62, while EPS last year was -$0.66. The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.33 and low estimates of -$0.64.
Analysts are recommending an EPS of between -$1.89 and -$2.18 for the fiscal current year, implying an average EPS of -$2.01. EPS for the following year is -$1.76, with 17 analysts recommending between -$1.36 and -$2.4.
